里昂:升藥明康德(2359.HK)目標價至115.63港元 評級“買入”
里昂發表報告指,藥明康德(2359.HK)
今年第三季收入按年上升34.7%至33.84億元人民幣,經調整純利按年上升64%至6.32億元人民幣,優於該行料全年增長33%的預測。而首九個月集團有超過900個正在進行的小分子CDMO/CMO(合約開發加工外包/合約加工外包)項目。考慮及第三季業績表現高於預期,及吸引新客户的強勁能力,該行上調藥明康德股份目標價,由98.84港元升至115.63港元,評級維持“
買入
”。
另外,里昂又上調集團明年及2021年收入預測至171.6億元及224.96億元人民幣;今年至2021年的經調整純利預測亦分別上調至22.58億元、30.2億元及39.7億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.